| 摘要 |
Pyrido[1,8]naphthyridinones of the general formula I <IMAGE> (I) in which R1 denotes hydrogen, a straight-chain or branched alkyl group having 1 to 6 carbon atoms, the phenyl group or a substituted phenyl group, a cycloalkyl group, a carboxyl group, an alkoxycarbonyl group, a carboxamide group or a cyano group, R2 denotes hydrogen or a straight-chain or branched alkyl group having 1 to 4 carbon atoms, R3 denotes hydrogen, a straight-chain or branched alkyl group having 1 to 4 carbon atoms, a carboxyl group, an alkoxycarbonyl group, a carboxamide group or a cyano group, R4 denotes hydrogen, halogen, the cyano group, the hydroxyl group, a carboxamide group, an alkylthio group or an alkoxy group, in each case having 1 to 6 carbon atoms, which may in each case optionally be substituted by substituted amino groups, furthermore denotes an aryloxy group, an amino group or a substituted amino group, a pyrrolidino, piperidino, hydrazino, morpholino, piperazine or substituted piperazino group, where the alkyl radicals may in each case be straight-chain or branched, and A denotes a pyridine ring, where ring A may also be present in partially hydrogenated form, and the tautomeric forms thereof, and the salts and acid-addition salts thereof, have positive inotropic and vasodilatory properties and can be used as medicaments for the treatment of heart insufficiency, angina pectoris and hypertonia. |
